Trial Profile
A Phase 2 Study of Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic Non-Small Cell Lung Carcinoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 23 Aug 2023
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Ramucirumab (Primary)
- Indications Carcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- 10 Apr 2023 Planned End Date changed from 1 Apr 2024 to 1 Apr 2025.
- 10 Apr 2023 Planned primary completion date changed from 1 Apr 2023 to 1 Apr 2024.
- 01 Apr 2021 Status changed from not yet recruiting to recruiting.